AI BioInsights Hub

Molecular glues induce selective protein degradation by promoting interactions between target proteins and E3 ligases, a mechanism discovered...

Takeda's up-to-$600 million collaboration with Insilico Medicine validates generative AI by outsourcing early molecule design to specialized...

Three advances show AI moving into diverse diagnostic roles:

• Cancer screening: Helio Genomics applies its MESA platform—merging cfDNA methylation,...

AI Drug Discovery Milestones

• 🔥 INS018_055 Phase IIa Results: INS018_055, the first AI-designed drug from Insilico Medicine, showed safety,...

• Phase III BREAKWATER trial links encorafenib plus cetuximab and mFOLFOX6 to OS benefits and fewer resistance alterations
• MRD-negative patients...

AI can advance health equity through better data analysis for prevention and care, yet biased datasets risk worsening disparities for minorities and...

INS018_055 Phase IIa success marks the first AI-designed drug readout, showing safety and lung function gains in IPF patients.

• This validates...

AI transforms personalized medicine from an unscalable vision into routine clinical practice by managing biological complexity at population...

• Consolidation in action: Claude Science merges literature review, hypothesis work, analysis, figures, and publication into one private...

Merck engineered calderasib to prioritize combinability over standalone potency in KRAS G12C inhibition, minimizing wild-type interactions while...

A rigorous benchmark reveals tabular foundation models like TabPFN deliver almost no performance gain over established machine learning for patient...

The FDA's July 1, 2026 approval expands Casgevy to sickle cell and beta-thalassemia patients as young as two, enabling intervention before...

AI Drug Discovery Initiatives

• 🔥 Anthropic Launches Internal Program: Anthropic is launching an internal drug discovery program focused on...

Genomic tools fail diverse populations due to biased data foundations. Around 85% of GWAS participants are European ancestry, causing polygenic scores...

Explainable AI training is essential for healthcare applications, enabling transparency and trust in AI diagnostics through emerging specialized programs.

• Illumina leads via NGS platforms for genomic testing in oncology and rare diseases
• Roche combines targeted therapies with companion diagnostics...

Gero merges physics models, AI, and large-scale human health data to identify drugs targeting shared aging mechanisms behind multiple chronic diseases. This hybrid approach shifts focus from single-disease treatments to broader healthspan extension.

AI is advancing precision oncology by combining genomic analysis with functional drug-response testing to deliver faster, personalized insights.

-...

AI speeds target identification, molecule design, and trial planning via LLMs, diffusion models, and GNNs, yet real-world cases show mixed results:...

Federal rules now release lab results to patients same-day, often before clinician review, sparking confusion and anxiety.

• LabGenie (AHRQ-funded)...